{"entity":{"id":"paolo-ascierto","kind":"person","name":"Paolo A. Ascierto","aka":[],"tldr":"Italian melanoma oncologist who co-led CheckMate 238, CheckMate 067 and the COLUMBUS BRAF/MEK trial.","summary":"Paolo Ascierto has been a lead investigator on most of the pivotal melanoma trials of the past decade, including CheckMate 238 (adjuvant nivolumab), CheckMate 067, COLUMBUS (encorafenib plus binimetinib) and the CheckMate 915 and RELATIVITY programmes. He founded the Melanoma Bridge and Immunotherapy Bridge meetings and leads one of Europe's largest melanoma units in Naples.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ascierto%20PA%5BAuthor%5D%20melanoma"}],"tags":["melanoma","immunotherapy","italy"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":["checkpoint-inhibitor","kinase-inhibitors"],"targets":["pd1","braf"],"drugs":["nivolumab","ipilimumab","encorafenib"],"companies":[],"institutions":["pascale-naples"],"pathways":[],"terms":[],"trials":["columbus","checkmate-067"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples","institutionId":"pascale-naples","specialisms":["Melanoma","Immunotherapy","Adjuvant therapy","Combination strategies"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ascierto%20PA%5BAuthor%5D%20melanoma"}],"papers":[{"title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma (CheckMate 238): 4-year results","journal":"Lancet Oncology","year":2020,"doi":"10.1016/S1470-2045(20)30494-0"},{"title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS)","journal":"Lancet Oncology","year":2018,"doi":"10.1016/S1470-2045(18)30142-6"}]},"route":"/people/paolo-ascierto/","neighbours":{"cancer":[{"id":"braf-v600-melanoma","kind":"cancer","name":"BRAF V600-mutant melanoma","route":"/cancers/braf-v600-melanoma/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"braf","kind":"target","name":"BRAF","route":"/targets/braf/"},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"drug":[{"id":"encorafenib","kind":"drug","name":"Encorafenib","route":"/drugs/encorafenib/"},{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"institution":[{"id":"pascale-naples","kind":"institution","name":"Istituto Nazionale Tumori IRCCS Fondazione G. Pascale","route":"/institutions/pascale-naples/"}],"trial":[{"id":"checkmate-067","kind":"trial","name":"CheckMate 067","route":"/trials/checkmate-067/"},{"id":"checkmate-238","kind":"trial","name":"CheckMate 238","route":"/trials/checkmate-238/"},{"id":"cobrim","kind":"trial","name":"coBRIM","route":"/trials/cobrim/"},{"id":"columbus","kind":"trial","name":"COLUMBUS","route":"/trials/columbus/"}]}}